financetom
Business
financetom
/
Business
/
Okta Could Beat Guidance Amid New Products, Rising Customer Interest, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Okta Could Beat Guidance Amid New Products, Rising Customer Interest, Oppenheimer Says
Sep 29, 2025 8:33 AM

10:59 AM EDT, 09/29/2025 (MT Newswires) -- Okta ( OKTA ) could outperform its financial projections amid product portfolio enhancements and growing customer interest, Oppenheimer said in a Monday client note.

Following the company's Oktane investor summit last week, the brokerage said it has become more bullish on Okta's ( OKTA ) product roadmap.

Oppenheimer analysts, including Ittai Kidron, highlighted an evolving product portfolio of the cloud-based access management platform, which plans to launch a tool that would manage, secure and govern AI agents next year. Other product announcements include verifiable digital credentials and Okta ( OKTA ) private cloud, according to the brokerage's note.

"Okta ( OKTA ) is managing to quickly evolve its portfolio, adding credibility to its efforts to become a broader platform play," Kidron wrote. "This, along with revenue upside potential, low investor expectations, and attractive valuation, leaves us bullish."

Most of Okta's ( OKTA ) customers expect to boost their spending on the company's products in the next 12 to 18 months, based an Oppenheimer survey of 15 customers at the investor summit. About two-thirds of the customers were keen on adding at least one new product, the poll showed, according to the research report.

Okta's ( OKTA ) guidance philosophy apparently hasn't changed, Oppenheimer said.

"While guidance no longer considers accommodations for macro uncertainty, it still accounts for risks associated with sales (and go-to-market) evolution," Kidron said. "Field sentiment remains high, channel partnerships are healthy, and new products uptake is positive. As a result, we see the potential for upside to guidance."

In August, Okta ( OKTA ) raised its full-year outlook after posting stronger-than-expected fiscal second-quarter results.

At the time, the company projected fiscal 2026 non-GAAP earnings per share of $3.33 to $3.38, up from the previous range of $3.23 to $3.28. Revenue was pegged at $2.88 billion to $2.89 billion, compared with the previous range of $2.85 billion to $2.86 billion. Analysts surveyed by FactSet currently expect non-GAAP EPS of $3.37 on revenue of $2.88 billion.

Oppenheimer has an outperform rating on the stock, with a price target of $120.

Price: 92.72, Change: +1.56, Percent Change: +1.71

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nexans signs an agreement to acquire Electro Cables Inc. strenghtening Nexans’ positioning in PWR-Connect in Canada
Nexans signs an agreement to acquire Electro Cables Inc. strenghtening Nexans’ positioning in PWR-Connect in Canada
Oct 22, 2025
Nexans signs an agreement to acquire Electro Cables Inc. strenghtening Nexans’ positioning in PWR-Connect in Canada Electro Cables is a Canadian player in low-voltage cable systems, delivering high-performance and service-focused solutionsStrong strategic complement to Nexans’ Canadian portfolio, offering attractive growth perspectives and a robust profitability profile Paris, October 23, 2025 — Nexans, a leader in the global energy transition, announces...
Why Ventyx (VTYX) Shares Soared 86.5% After Hours?
Why Ventyx (VTYX) Shares Soared 86.5% After Hours?
Oct 22, 2025
Ventyx Biosciences Inc. ( VTYX ) jumped 86.53% to $7.20 in after-hours trading on Wednesday after the company reported positive Phase 2 trial results for its obesity and cardiovascular risk drug candidate, VTX3232. Check out the current price of VTYX stock here.  Phase 2 Data In a study involving 175 participants, VTX3232 monotherapy led to a 78% reduction in hsCRP...
Roche raises guidance on forecast-beating nine-month sales
Roche raises guidance on forecast-beating nine-month sales
Oct 22, 2025
FRANKFURT (Reuters) -Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected. In a statement, the group said it expects a currency-adjusted increase in 2025 sales in the mid single digit percentage range. It also projected a gain in adjusted earnings per share in the high single to low double digit percentage...
Alibaba launches AI chatbot service in renewed consumer push
Alibaba launches AI chatbot service in renewed consumer push
Oct 22, 2025
BEIJING, Oct 23 (Reuters) - Alibaba ( BABA ) launched a new AI chatbot assistant service on Thursday, refreshing its push into a consumer-facing space that is dominated by ByteDance and Tencent ( TCTZF ). The Chinese e-commerce firm integrated the chat assistant into its Quark app, a platform that began as a browser but has been repositioned this year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved